Cadila Healthcare receives final USFDA approval for Allopurinal tablets
Tanay Loya / 16 Oct 2017
Zydus Cadila has received final approval from the USFDA to market Allopurinol Tablets USP, 100 mg and 300 mg.
Zydus Cadila has received final approval from the USFDA to market Allopurinol Tablets USP, 100 mg and 300 mg.
The drug is used to treat major depression and will be manufactured at the group's formulations manufacturing facility at Ahmedabad. The USFDA nod for Allopurinal tablets augurs well for Cadila Healthcare, as it would help the company improve its US revenues. The sales of Allopurinol tablets USP are estimated to be at more than Rs. 920 crore.
Cadila Healthcare is a pharmaceutical company with strong presence in the formulations and CRAMS businesses globally. The group now has more than 160 approvals and has filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
At 9:50 am, Cadila Healthcare was trading at Rs 505.10, up by Rs 3.70 or 0.74 per cent from its previous closing price of Rs 501.40. The scrip opened at Rs 504.40 and touched a high and low of Rs 506.95 and Rs 504.00 respectively. The stock attracted a traded volume of 6209 shares on the BSE. The share touched its 52-week high of Rs 558 and 52-week low of Rs 342 on June 12, 2017 and December 26, 2016, respectively.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.